With the advent of clinically effective immunotherapies for neurodegenerative diseases, including Aducanumab resulting from research conducted at the University of Zurich, antibody-based regenerative therapies are becoming a clinical reality.  Aducanumab removes beta-amyloid plaques from brains of patients with Alzheimer's disease, followed by stabilization of cognitive and functional abilities.  In addition to cell-based therapies and tissue replacement, antibody-based therapies designed to enable endogenous regeneration are becoming an important addition to the therapeutic tool kit in regenerative medicine (Nature. September 1, 2016. doi:10.1038/nature19323).